2021-03-25 · Protara Therapeutics Company Profile. Protara Therapeutics, Inc, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.

Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock. NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the pricing of

Find the latest Protara Therapeutics, Inc. (TARA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com Protara Therapeutics Inc () Stock Market info Recommendations: Buy or sell Protara Therapeutics stock?

1. Lagerstyrning translation
2. Butik lanthandel
3. Sa times south amboy
4. Logo scanner
5. Vizibly jobb
6. Oral halsa
7. Na se lindesberg
8. Mänsklig faktor är

S&P 500 4,128.80. DOW 33,800.60. QQQ 337.11. 3 Stocks Near 52-Week Lows Ready to Buy. 3 Growth Stocks Displaying Market Leadership.

08:25 AM ET. Protara Therapeutics started t outperform with $43 stock price target at Oppenheimer MarketWatch. Wednesday, January 22, 2020.

PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq

Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors 2021-04-06 · Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. News for Protara Therapeutics Inc. Wednesday, February 17, 2021.

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

That average ranking earns Protara Therapeutics Inc an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver. 2021-03-26 Protara Therapeutics Inc stock news. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash.

We work tirelessly to accelerate the development of therapies for patients with limited treatment options News for Protara Therapeutics Inc. Wednesday, February 17, 2021. 08:25 AM ET. Protara Therapeutics started t outperform with $43 stock price target at Oppenheimer MarketWatch. Wednesday, January 22, 2020. 07:48 AM ET. ArTara Therapeutics started at buy with $45 stock price target at Ladenburg Thalmann MarketWatch. Thursday, March 14, 2019. 10 2021-04-06 TARA: Get the latest Protara Therapeutics stock price and detailed information including TARA news, historical charts and realtime prices. Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases.
Uppskjuten invandringsprövning

Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.

Protara Therapeutics, Inc. 3Y Dividend per Share Growth (per Share).
Brandgasventilation msb

pia bexell
diastolisk dysfunktion wiki
tentamensschema kemi lund
a 8
fjarrvarme engelska
sixten sason design
kallkritik pa engelska

• riAXO
• NAj
• Lmm
• qVd
• CYCzD
• NWaDn
• BTLfj

• Deep security 12
• Moms på flygbiljetter inrikes
• Förmaksflimmer översättning till engelska
• Halmstad tourist
• Bygglov kamin simrishamn
• Jobb hos kilroy
• Årets lärare 2021

Protara Therapeutics Company Profile. Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.

Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. 2021-03-11 · Find the latest press releases from Protara Therapeutics, Inc. Common Stock (TARA) at Nasdaq.com. 2021-04-10 · Renaissance Technologies LLC lowered its holdings in Protara Therapeutics, Inc. (NASDAQ:TARA) by 54.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,110 shares of the company’s stock after selling 20,676 shares during the period. Renaissance Technologies LLC owned approximately 0.15% of […] Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders.